Rhythm Pharmaceuticals, Inc.RYTMNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank56
3Y CAGR-21.5%
5Y CAGR-9.9%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-21.5%/yr
vs +1.3%/yr prior
5Y CAGR
-9.9%/yr
Recent deceleration
Acceleration
-22.8pp
Decelerating
Percentile
P56
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 9.64% |
| Q3 2025 | 14.10% |
| Q2 2025 | 17.55% |
| Q1 2025 | 2.51% |
| Q4 2024 | 7.78% |
| Q3 2024 | -2.85% |
| Q2 2024 | 5.91% |
| Q1 2024 | 6.20% |
| Q4 2023 | 6.23% |
| Q3 2023 | 1.43% |
| Q2 2023 | 21.97% |
| Q1 2023 | -6.40% |
| Q4 2022 | 19.96% |
| Q3 2022 | -1.75% |
| Q2 2022 | 4.10% |
| Q1 2022 | 2.15% |
| Q4 2021 | 19.93% |
| Q3 2021 | 13.20% |
| Q2 2021 | 6.52% |
| Q1 2021 | 10.66% |
| Q4 2020 | 16.21% |
| Q3 2020 | 26.54% |
| Q2 2020 | -30.28% |
| Q1 2020 | 35.93% |
| Q4 2019 | -10.64% |
| Q3 2019 | 19.16% |
| Q2 2019 | 13.95% |
| Q1 2019 | -7.50% |
| Q4 2018 | -1.77% |
| Q3 2018 | 32.65% |
| Q2 2018 | 36.52% |
| Q1 2018 | 8.89% |
| Q4 2017 | 87.04% |
| Q3 2017 | 70.60% |
| Q2 2017 | -10.49% |
| Q1 2017 | -44.75% |
| Q4 2016 | 179.43% |
| Q3 2016 | -11.77% |
| Q2 2016 | -24.39% |
| Q1 2016 | -27.31% |